Compositions and methods for analyzing modified nucleotides
A method for identifying any of the presence, location and phasing of modified cytosines (C) in long stretches of nucleic acids is provided. In some embodiments, the method may comprise (a) reacting a first portion of a nucleic acid sample containing at least one C and/or at least one modified C with a DNA glucosyltransferase and a cytidine deaminase to produce a first product and/or reacting a second portion of the sample with a dioxygenase, optionally a DNA glucosyltransferase and a cytidine deaminase to produce a second product and; (b) comparing the sequences from the first and optionally the second product obtained in (a), or amplification products thereof, with each other and/or an untreated reference sequence to determine which Cs in the initial nucleic acid fragment are modified. A modified TET methylcytosine dioxygenase with improved efficiency compared to unmodified TET2 at converting methylcytosine to carboxymethylcytosine is also provided.
1. A protein comprising SEQ ID NO:2 and having methyl cytosine dioxygenase activity.
2. The protein of claim 1 , wherein the protein is a fusion protein.
3. The protein of claim 1 , wherein the fusion protein has an N-terminal affinity binding domain.
4. A kit comprising a protein of claim 1 contained in one vessel, and optionally a cytidine deaminase in a second vessel and instructions for use.
5. The kit of claim 4 , wherein the concentration of the protein in the one vessel provides a concentration of 0.001-100 micrograms in a reagent or in a reaction mix.
6. The kit of claim 5 , wherein the one vessel further comprises 0.001-100 units of a glucosyltransferase in the reagent or the reaction mix.
7. A composition comprising the protein of claim 1 , wherein the composition further comprises a nucleic acid, wherein the nucleic acid comprises:
a. guanine (G), adenine (A), thymine (T), uracil (U), cytosine (C);
b. G, A, T, U, carboxycytosine and no C; or
c. G, A, T, U, no C and a modified hydroxymethylcytosine wherein the modification is capable of blocking oxidation by a methylcytosine dioxygenase.